Drug intelligence / Profile preview

MB-301 (March Biosciences)

Development stage: Preclinical
Lead developer: March Biosciences

Overview

MB-301 is a preclinical-stage drug candidate being developed by March Biosciences for the treatment of hematologic neoplasms (blood cancers). While March Biosciences is a clinical-stage company that specializes in the development of chimeric antigen receptor (CAR) T-cell therapies, the specific therapeutic modality and biological target for MB-301 have not been publicly disclosed. The program represents an early-stage expansion of the company's oncology pipeline, which also includes more advanced candidates targeting CD5 and CD7.

Targets

CD5 (T-cell surface glycoprotein CD5)

Beyond the preview

Go deeper on MB-301 (March Biosciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-301 (March Biosciences).

Explore the full profile